DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.
You may also be interested in...
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.